newsfilter
← Latest News
GlobeNewswire·

RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update

-- Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- -- Expanded Board of Directors with the appointment of Al